Amring Pharmaceuticals
  • Generics
  • Partner
  • Company
  • News
  • Contact
Select Page

Amring Pharmaceuticals Inc. Acquires LYSTEDA®

by Will Figueiredo | Dec 2, 2020 | Uncategorized

December 2, 2020 Amring Pharmaceuticals Inc., a generic pharmaceutical company, announced the acquisition of the global rights to LYSTEDA® (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy...

Recent Posts

  • Amring Pharmaceuticals Inc. issues nationwide Class III recall for 2 lots of Tranexamic Acid Tablets
  • Amring Pharmaceuticals Inc. Joins End Drug Shortages Alliance
  • Amring Pharmaceuticals Inc. Announces the Launch of Timolol Maleate Ophthalmic Solution, USP 0.5%
  • Amring Pharmaceuticals Inc. Announces the Approval and Launch of Generic Lamotrigine Orally Disintegrating Tablets (ODT), USP
  • Amzell B.V. and Amring Pharmaceuticals Inc. Attending 2021 American Epilepsy Society Meeting

Recent Comments

    Archives

    • June 2023
    • July 2022
    • June 2022
    • February 2022
    • December 2021
    • November 2021
    • October 2021
    • August 2021
    • March 2021
    • December 2020
    • August 2020
    • June 2019
    • January 2019
    • July 2018
    • June 2017
    • March 2017
    • April 2016
    • March 2016
    • January 2016
    • December 2015
    • June 2015

    Categories

    • News
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Amring

    Get in touch

    844.304.4828 More contact options

    Get to know Amring

    Products Partner Company LinkedIn

    What’s new

    Amring Pharmaceuticals Inc. announced that it has received FDA approval for generic Timolol Maleate Ophthalmic Solution, USP 0.5%, 60 pack of 0.3mL unit dose vials (AT3 rated generic equivalent of Timoptic® in Ocudose®) and has begun commercialization activities.

    More news & events